Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan, Wenzhou Zhang
Summary: Despite advancements in diagnosis and treatment, lung cancer mortality remains high. This review provides an overview of current diagnostic methods and therapies for non-small cell lung cancer, serving as a guide for clinicians.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Zaid Sirhan, Rawan Alojair, Anita Thyagarajan, Ravi P. Sahu
Summary: Lung cancer is a major malignancy globally, with NSCLC being the most common type. PTEN, a tumor suppressor gene, plays a critical role in regulating cancer growth and its dysfunction is associated with poor prognosis in lung cancer patients. PTEN has been explored as a promising target for anti-cancer agents, as it can interact with multiple signaling pathways to devise effective treatment options for NSCLC.
Review
Medicine, Research & Experimental
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Summary: Non-small cell lung cancer (NSCLC) is the most common and deadly malignancy of lung cancer; chemotherapy is gradually withdrawn from the stage of history due to its obvious side effects; researchers are now focusing on targeted drugs for the treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Oncology
Tania Losanno, Cesare Gridelli
Summary: Treatment of elderly patients with NSCLC is challenging due to higher risk of comorbidities and deteriorations in physical, organ, and cognitive functions. Targeted therapy and immunotherapy are becoming important options for first-line treatment in elderly patients due to their manageability and fewer side effects compared to cytotoxic chemotherapy. Further investigations are needed to determine the best treatment option for each elderly patient.
CURRENT ONCOLOGY REPORTS
(2021)
Review
Oncology
Khaled Sanber, Samuel Rosner, Patrick M. Forde, Kristen A. Marrone
Summary: Immune checkpoint blockade (ICB) has shown improved outcomes in advanced non-small cell lung carcinoma (NSCLC). Utilizing ICB early in the disease course, particularly in the neoadjuvant setting prior to surgery, has been suggested to have advantages. Clinical trials have demonstrated improved pathological responses and longer event-free survival when neoadjuvant ICB is added to chemotherapy. However, many questions remain to be addressed, including the optimal duration of neoadjuvant therapy and the clinical management of residual disease and recurrence.
Article
Oncology
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyurek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan Sayin
Summary: This retrospective study investigated the impact of KRAS mutational status on clinical outcome in patients with metastatic non-small cell lung cancer (NSCLC). The results showed that KRAS(MUT) patients had better response to immune checkpoint blockade (ICB) but worse response to platinum doublet chemotherapy (PT). Additionally, KRAS(WT) patients with high PD-L1 expressing tumors responded better to PT than ICB.
Editorial Material
Oncology
Yu Chen, Jinming Yu, Xiangjiao Meng
Summary: This commentary emphasizes the potential of postoperative radiotherapy in patients with completely resected IIIA-N2 non-small cell lung cancer.
Article
Oncology
Antonio Passaro, Ilaria Attili, Filippo de Marinis
Summary: The Oncology Grand Rounds series aims to help readers better apply the research findings published in the Journal of Clinical Oncology to patients in their own clinical practice. It includes case presentations, descriptions of diagnostic and management challenges, literature reviews, and suggested treatment approaches.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Anna Manzo, Vincenzo Sforza, Guido Carillio, Giuliano Palumbo, Agnese Montanino, Claudia Sandomenico, Raffaele Costanzo, Giovanna Esposito, Francesca Laudato, Edoardo Mercadante, Carmine La Manna, Paolo Muto, Giuseppe Totaro, Rossella De Cecio, Carmine Picone, Maria Carmela Piccirillo, Giacomo Pascarella, Nicola Normanno, Alessandro Morabito
Summary: Lurbinectedin, a novel therapeutic approach for small cell lung cancer, has shown activity in patients who have failed previous chemotherapy. It has been approved as a second-line treatment and is currently being studied in combination with other drugs.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yvonne H. F. Teng, Hong Sheng Quah, Lisda Suteja, Joao M. L. Dias, Annalisa Mupo, Rachael J. M. Bashford-Rogers, George S. Vassiliou, Melvin L. K. Chua, Daniel S. W. Tan, Darren W. T. Lim, N. Gopalakrishna Iyer
Summary: Recent studies have found shared T cell receptor (TCR) clonotypes in different types of head and neck cancers, with distinct characteristics including shorter CDR3 lengths, restricted V and J gene usages, and convergent V(D)J recombination. These shared TCRs may be enriched for specificity to common antigens found in the tumor microenvironment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Correction
Oncology
Yvonne H. F. Teng, Hong Sheng Quah, Lisda Suteja, Joao M. L. Dias, Annalisa Mupo, Rachael J. M. Bashford-Rogers, George S. Vassiliou, Melvin L. K. Chua, Daniel S. W. Tan, Darren W. T. Lim, N. Gopalakrishna Iyer
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Naoyuki Nogami, Fabrice Barlesi, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony S. K. Mok, Gene Finley, Joachim G. Aerts, Francisco Orlandi, Denis Moro-Sibilot, Robert M. Jotte, Daniil Stroyakovskiy, Liza C. Villaruz, Delvys Rodriguez-Abreu, Darren Wan-Teck Lim, David Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bara, Makoto Nishio
Summary: This study presents the final overall survival (OS) analyses for EGFR mutations and liver or brain metastases subgroups in the IMpower150 study. The results show that ABCP has sustained OS improvements compared to BCP in sensitizing EGFR mutations and baseline liver metastases subgroups. However, ACP does not provide a survival benefit in these subgroups compared to BCP. The study also suggests further investigation into the impact of ABCP on delaying the development of new brain lesions.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, Shunji Takahashi, John Sarantopoulos, Andrea Varga, Joseph A. D'Alessio, Tinya Abrams, Qing Sheng, Eugene Youchin Tan, Maria Santos Rosa, Juan Gonzalez-Maffe, Janna Sand-Dejmek, Claire Fabre, Miguel Martin
Summary: This study investigated the safety, tolerability, pharmacokinetics, and preliminary efficacy of PCA062 in patients with solid tumors. The findings showed limited antitumor activity at the maximum tolerated dose of PCA062, and no correlation between tumor P-cadherin expression and clinical efficacy.
MOLECULAR CANCER THERAPEUTICS
(2022)
Correction
Biochemistry & Molecular Biology
Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Wangjun Liao, Xiaohui He, Xiaozhong Chen, Zhigang Liu, Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching-Yun Hsieh, Muh-Hwa Yang, Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu
Article
Oncology
Stephanie P. L. Saw, Win Pin Ng, Siqin Zhou, Gillianne G. Y. Lai, Aaron C. Tan, Mei -Kim Ang, Wan-Teck Lim, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Wan Ling Tan, Tanujaa Rajasekaran, Johan W. K. Chan, Yi Lin Teh, Mengyuan Pang, Jia-Chi Yeo, Angela Takano, Boon-Hean Ong, Eng-Huat Tan, Sze Huey Tan, Anders J. Skanderup, Daniel S. W. Tan
Summary: The aim of this study was to compare the prognostic value of programmed death-ligand 1 (PD-L1) score in early-stage epidermal growth factor receptor (EGFR)-mutated and EGFR-wildtype non-small cell lung cancer (NSCLC). The results showed that PD-L1 > 1% was an independent predictor of worse prognosis in EGFR-mutated NSCLC and was associated with inferior disease-free survival (DFS) regardless of EGFR status. Therefore, PD-L1 score should be evaluated as a risk stratification factor in prospective adjuvant studies among EGFR-mutated NSCLC.
EUROPEAN JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Aaron C. Tan, Keigo Kobayashi, Stephanie P. L. Saw, Daniel S. W. Tan, Darren Wan-Teck Lim
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Editorial Material
Oncology
Wan Ling Tan, Darren Wan-Teck Lim
JOURNAL OF THORACIC ONCOLOGY
(2023)
Review
Oncology
Brian Sheng Yep Yeo, Harris Jun Jie Muhammad Danial Song, Yoke Lim Soong, Melvin Lee Kiang Chua, Mei-Kim Ang, Darren Wan Teck Lim, Anna See, Chwee Ming Lim
Summary: This study aims to summarize the evidence on the use of anti-PD1 antibodies in recurrent and/or metastatic nasopharyngeal cancer patients and compare their effectiveness with chemotherapy. The results show that anti-PD1 antibodies have significant activity in the treatment of these patients. Combination therapy with gemcitabine and cisplatin enhances the efficacy of treatment.
Article
Multidisciplinary Sciences
Darren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, Constance H. Li, Hong Sheng Quah, Daniel Shao-Weng Tan, Sze-Huey Tan, Eng-Huat Tan, Wan-Ling Tan, Justina Nadia Lee, Felicia Yu-Ting Wee, Amit Jain, Boon-Cher Goh, Melvin L. K. Chua, Bin-Chi Liao, Quan Sing Ng, Ruey-Long Hong, Mei-Kim Ang, Joe Poh-Sheng Yeong, N. Gopalakrishna Iyer
Summary: This study reports the results of a clinical trial of dual PD-1 and CTLA-4 checkpoint blockade in patients with recurrent/metastatic EBV-positive nasopharyngeal carcinoma. Single-agent checkpoint inhibitor activity is limited in this cancer type, but the combination treatment shows increased activity. The results show that this combination therapy has good tolerability and better clinical response and progression-free survival in patients with low EBV-DNA levels.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Jun Ma, Sze Huey Tan, Daniel Xing Cheng Yin, Nguyen Tuan Anh Tran, Gek San Tan, Gillianne Geet Yi Lai, Mei-Kim Ang, Ravindran Kanesvaran, Amit Jain, Tanujaa Rajasekaran, Eng-Huat Tan, Tony Kiat Hon Lim, Daniel Shao-Weng Tan, Darren Wan-Teck Lim, Quan Sing Ng, Wan Ling Tan
Summary: This study retrospectively examined the performance of osimertinib in the second/subsequent line treatment of lung cancer patients. The results showed that osimertinib had good efficacy in the second-line setting and there was heterogeneity in T790M expression between plasma and tumor tissue, indicating that plasma T790M testing may not fully predict the efficacy of osimertinib.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Kah Yee Goh, Terence You De Cheng, Su Chin Tham, Darren Wan-Teck Lim
Summary: Non-small cell lung cancer (NSCLC) is the dominant form of lung cancer and typically has a poor prognosis. Immunotherapy using immune checkpoint inhibitors (ICI) has shown superior efficacy compared to conventional chemotherapy for advanced NSCLC patients. However, there is a need for biomarkers to accurately predict immunotherapy response, as only a minority of patients benefit from this treatment. Liquid biopsy, which enables non-invasive sampling of blood-based biomarkers, allows for the dynamic monitoring of treatment response. This review summarizes the progress and challenges in identifying circulating biomarkers for predicting immunotherapy benefit in NSCLC patients.
Meeting Abstract
Oncology
P. L. S. Saw, G. S. Tan, A. Tan, G. Lai, W. C. Tan, E. H. Tan, M-K. Ang, D. W-T. Lim, R. Kanesvaran, Q. S. Ng, A. Jain, W. L. Tan, T. Rajasekaran, J. Chan, Y. L. Teh, S. H. Tan, T. K. H. Lim, D. S. W. Tan
JOURNAL OF THORACIC ONCOLOGY
(2023)
Review
Oncology
Victor Ho-Fun Lee, Marlinda Adham, Wala Ben Kridis, Paolo Bossi, Ming-Yuan Chen, Imjai Chitapanarux, Vincent Gregoire, Sheng Po Hao, Cheryl Ho, Gwo Fuang Ho, Danita Kannarunimit, Dora Lai-Wan Kwong, Ka-On Lam, Wai Kei Jacky Lam, Quynh-Thu Le, Anne Wing-Mui Lee, Nancy Y. Lee, To-Wai Leung, Lisa Licitra, Darren Wan-Teck Lim, Jin-Ching Lin, Kwok Seng Loh, Pei-Jen Lou, Jean-Pascal Machiels, Hai-Qiang Mai, Ricard Mesia, Wai-Tong Ng, Roger Kai-Cheong Ngan, Joshua K. Tay, Raymond King-Yin Tsang, Chi-Chung Tong, Hung-Ming Wang, Joseph T. Wee
Summary: The COVID-19 pandemic has had a significant impact on the healthcare industry, particularly in the field of otorhinolaryngology. This study provides consensus recommendations on the management of nasopharyngeal carcinoma in the context of the current pandemic and potential future airborne diseases or disasters, with a focus on the use of plasma EBV DNA as a biomarker.
Meeting Abstract
Oncology
A. Dimitrios Colevas, Lillian L. Siu, Darren Wan-Teck Lim, Bo Gao, Lisa Rojkjaer, Afton Katkov, Yisrael Katz, Brigette Ma
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Rui Wang, Aashiq Hussain, Quanquan Guo, Meimei Ma
Summary: DNA is highly immunogenic and can activate the cGAS-STING pathway, which plays a crucial role in the pathogenesis and progression of neoplastic diseases. The modulation of cGAS-STING signaling holds great promise for cancer therapy, although there are disagreements on whether to activate or inhibit this pathway.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Ali Zarezadeh Mehrabadi, Faezeh Shahba, Hossein Khorramdelazad, Nazanin Aghamohammadi, Milad Karimi, Kowsar Bagherzadeh, Majid Khoshmirsafa, Ramin Massoumi, Reza Falak
Summary: IL-1 receptor accessory protein (IL-1RAP) plays a crucial role in inflammatory conditions and tumorigenesis in the tumor microenvironment. It is involved in the progression, metastasis, and angiogenesis of solid tumors and hematological malignancies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Xiao Tang, Yujie Niu, Jinli Jian, Yuancheng Guo, Yin Wang, Yu Zhu, Bei Liu
Summary: Ferroptosis is an iron-dependent form of cell death that promotes tumor cell death by causing cell membrane rupture and accumulation of lipid peroxides. Extensive research has been conducted to explore the mechanism of ferroptosis inducers, but its role in hematological tumors is still limited.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Tanwei Yuan, Dominic Edelmann, Jakob N. Kather, Ziwen Fan, Katrin E. Tagscherer, Wilfried Roth, Melanie Bewerunge-Hudler, Alexander Brobeil, Matthias Kloor, Hendrik Blaeker, Barbara Burwinkel, Hermann Brenner, Michael Hoffmeister
Summary: The study aimed to analyze and validate previously published CpG-methylation-based prognostic biomarkers and prediction models for colorectal cancer (CRC) prognosis. The results showed that the discrimination ability of the models was insufficient and lacked clinical relevance.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen, Daichao Wu
Summary: This article provides a comprehensive overview of therapeutic cancer vaccines, including their classification, clinical application, efficacy, and combination strategies with other therapies. It offers a valuable theoretical basis for the future clinical application and development of therapeutic cancer vaccines.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)